Civica Rx, the nonprofit generic drug company formed last year by 5 health systems in order to combat drug shortages and high prices for generic drugs, added 12 additional health systems this week, bringing the total to 750 hospitals in the United States joining the venture so far.
Civica Rx, the nonprofit generic drug company formed last year by 5 health systems in order to combat drug shortages and high prices for generic drugs, added 12 additional health systems this week, bringing the total to 750 hospitals in the United States joining the venture so far.
“We are thrilled to welcome these highly-regarded health systems to Civica as founding members,” said Martin VanTrieste, Civica Rx’s chief executive officer, in a statement. “Drug shortages have become a national crisis where patient treatments and surgeries are canceled, delayed, or suboptimal. We thank these organizations for joining us to make essential generic medicines accessible and affordable in hospitals across the country.”
The aim of the initiative is to reduce costs and create a more predictable supply of many medicines.
The 12 systems joining as founding members are:
The latest members join the previously announced governing members, which include Catholic Health Initiatives, the Gary and Mary West Foundation, HCA Healthcare, Intermountain Healthcare, Laura & John Arnold Foundation, Mayo Clinic, the Peterson Center on Healthcare, Providence St. Joseph Health, SSM Health, and Trinity Health.
In 2019, Civica Rx hopes to bring over 14 hospital-administered generic drugs to hospitals and healthcare systems. Additional medications, as prioritized by the healthcare systems, will be the next phase of focus. The company is working toward becoming an FDA approved manufacturer and will either directly manufacture generic drugs or sub-contract manufacturing.
Hospitals have been struggling with drug shortages and the problem is getting worse, Martin Makary, MD, MPH, a surgical oncologist, said on a recent Managed Care Cast podcast.
Last year, the FDA decided to start extending the expiration dates of IV saline fluids in order to help hospitals cope with the shortages.
If Civica RX is successful, hospitals could see price reductions of 50%, The Chicago Tribune reported Friday. The new company will initially focus on selling to hospitals, but may eventually expand to offer products more broadly.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The Future of Biosimilar Gene Therapies: Key Issues and Potential
September 11th 2024While biosimilars could potentially lower costs and improve access to gene therapies, significant hurdles in regulation, manufacturing, intellectual property, and market size pose challenges to their development and market entry.
BioRationality: FDA Clarification Provides New Indications and Process Change for Biosimilars
September 9th 2024Sarfaraz K. Niazi, PhD, explains the FDA's new guidelines on post-approval changes for biosimilars, emphasizing the processes for reporting modifications, comparability assessments, and the potential for biosimilars to introduce new indications or formulation changes, which could significantly impact their market competitiveness and accessibility.